While major advances in screening, targeted treatment and immunotherapy have transformed outcomes for non-small cell lung cancer, progress against small cell lung cancer (SCLC) has lagged behind. In this episode, Jacob Sands, MD, of Dana-Farber Cancer Institute and Harvard Medical School joins us to share insights into the present state of SCLC treatment, from staging and standard therapies to new research on vaccines that could one day change the course of this aggressive disease.